Abstract
Neutralizing activity of secretory immunoglobulin A (S-IgA) directed against the V1/V2 domain of HIV-1 was studied in parotid saliva of HIV-1- infected patients in Colombian and French cohorts. Purified V1/V2-specific S-IgA antibodies were found to neutralize clades A, B and C primary isolates in five out 76 and 82 patients from each cohort, respectively. These results suggest that neutralizing S-IgA antibodies targeting the V1/V2 domain may provide protection against HIV-1 infection in vivo and may be beneficial in mucosal vaccines.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Neutralizing / immunology*
-
Cohort Studies
-
Colombia
-
Female
-
France
-
HIV Envelope Protein gp120 / immunology
-
HIV Infections / immunology*
-
HIV-1 / immunology*
-
Humans
-
Immunoglobulin A, Secretory / immunology*
-
Male
-
Peptide Fragments / immunology
-
Saliva / immunology*
-
Saliva / virology
Substances
-
Antibodies, Neutralizing
-
HIV Envelope Protein gp120
-
HIV envelope protein gp120 (135-148)
-
Immunoglobulin A, Secretory
-
Peptide Fragments